



SEP 15 1999

Docket No. 4-30598/A/SYS2068
Serial No. 09/237,291

#5
JF
9/21/99
w/cont

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Assistant Commissioner for Patents, Washington, DC 20231, on September 1, 1999.

Christa Carter
Christa Carter

IN THE UNITED STATES PATENT AND TRADEMARK DEPARTMENT

Applicant:	Young, et al.)	Examiner:	M. Schmidt
Serial No.:	09/237,291)	Group Art Unit:	1636
Filing Date:	January 25, 1999)		
For:	Expanded and Genetically Modified Populations of Human Hematopoietic Stem Cells)		

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed please find the following:

- a) Supplemental Information Disclosure Statement;
- b) Information Disclosure Statement Form PTO 1449;
- c) Fee Letter for IDS (in duplicate); and
- d) Search Report and references cited therein
- d) Postcard Receipt.

The Assistant Commissioner is hereby authorized to charge any fees that may be required by this transmittal, or to credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Lynn Marcus-Wyner
Lynn Marcus-Wyner
Attorney for Applicant(s)
Reg. No. 34,869

September 1, 1999

SYSTEMIX, INC.
NOVARTIS CORPORATION
Patent Department
1651 Page Mill Road
Palo Alto, California 94304
Tel. No. 650-813-5132
Fax No. 650-813-4131



CASE 4-30598/A/SYS2068

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Christa Carter
Type or print name

Christa Carter
Signature

September 1, 1999
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1636

YOUNG, ET AL.

APPLICATION NO: 09/237,291

FILED: JANUARY 25, 1999

FOR: EXPANDED AND GENETICALLY MODIFIED POPULATIONS OF
HUMAN HEMATOPOIETIC STEM CELLS

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee as set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form PTO-1449.

The listed references were cited in the International Search Report by the European Patent Office for the corresponding PCT application, PCT/EP99/00597, and a copy of the Search Report is enclosed. Copies of the references are enclosed herewith.

09/10/1999 CCETIN 00000073 190134 09237291
01 FC:126 240.00 CH

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.


Respectfully submitted,



Lynn Marcus-Wyner
Attorney for Applicants
Reg. No. 34,869

Systemix, Inc.
Patent Department
1651 Page Mill Road
Palo Alto, CA 94304
(650) 813-5132

Date: September 1, 1999




CASE 4-30598/A/SYS2068

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Christa Carter
Type or print name


Signature

September 1, 1999
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1636

YOUNG, ET AL.

APPLICATION NO: 09/237,291

FILED: JANUARY 25, 1999

FOR: EXPANDED AND GENETICALLY MODIFIED POPULATIONS OF
HUMAN HEMATOPOIETIC STEM CELLS

Assistant Commissioner for Patents
Washington, D.C. 20231


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$240 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,


Lynn Marcus-Wyner
Attorney for Applicant
Reg. No. 34,869

Systemix, Inc.
Patent Department
1651 Page Mill Road
Palo Alto, CA 94304
(650) 813-5132
Date: September 1, 1999